The average American on the street has a Facebook account, an opinion about Facebook, heard about the Facebook initial public offering, and knows it collapsed. That same person doesn’t see how their life connects with biotech, probably can’t name a single biotech company, and certainly hasn’t heard of any members of the biotech IPO class of 2012.
But here’s something that might surprise both biotech insiders and the average guy or gal on the street. The biotech IPO class of 2012 has made money for investors, while tech’s most glamorous up-and-comers have been stumbling.
{iframe}http://www.xconomy.com/national/2012/08/13/biotech-ipos-are-beating-techs-big-names/?utm_source=rss&utm_medium=rss&utm_campaign=biotech-ipos-are-beating-techs-big-names&utm_source=Xconomy&utm_campaign=6f278d92d0-NEWSLETTER_ALL_STORIES&utm_medium=email{/iframe}